טוען...
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the...
שמור ב:
| הוצא לאור ב: | J Exp Med |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Rockefeller University Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5940263/ https://ncbi.nlm.nih.gov/pubmed/29626114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171484 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|